<DOC>
	<DOCNO>NCT02716233</DOCNO>
	<brief_summary>A still major question field acute lymphoblastic leukemia ( ALL ) child - extremely heterogeneous disease though curable 80-90 % child 70-80 % adolescent - optimal use L-asparaginase ( ASNase ) . It know administer ASNase result depletion asparagine circulate blood , starve leukemic cell result death . But indeed use ASNase varies protocols consider different brand , dose administration modality . Oncaspar ( PEGylated E. coli asparaginase , pegaspargase ) thus developed goal reduce immunogenicity native ASNase . This French prospective multicentric cohort study child adolescents ALL , stratify ( ) type ALL ( B v T ) ( ii ) anticipate risk ( stratified 3 group childhood B-cell precursor ( BCP ) -ALL 2 group T-cell ALL ) . It aim answer two different issue : 1 . Randomized question : best way administer pegaspargase ? A cohort child adolescents standard medium risk ALL randomize receive induction either one infusion ONCASPAR® 2500 IU/m2 D12 two infusion ONCASPAR® 1250 IU/m2 D12 D26 . Patients receive 2500 IU/m2 1250 IU/m2 per dose consolidation delay intensification accord initial arm randomization . 2 . Non randomized question : In High/Very High Risk group , non randomize intensification scheme asparaginase administration propose induction therapy : 2 infusion 2500 IU/m2/day ( D12 D26 ) administer . All patient receive 2500 IU/m2 per dose consolidation delay intensification .</brief_summary>
	<brief_title>A French Protocol Treatment Acute Lymphoblastic Leukemia ( ALL ) Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>ALL L1 L2 Blineage T lineage ALL L3 ( Burkitt 's leukemia ) Mixed Phenotype Acute Leukemia ( WHO criteria ) . Infant ALL ( age ≤ 365 day ) Philadelphia ( Ph ) +/Breakpoint Cluster region ( BCR ) Abelson ( ABL ) ALL</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>